Temozolomide for treating brain metastases.
暂无分享,去创建一个
[1] G. Margison,et al. Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells. , 2000, The Journal of pharmacology and experimental therapeutics.
[2] P. Beale,et al. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies , 1999, British Journal of Cancer.
[3] G. Weiss,et al. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] D. V. Von Hoff,et al. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] B. Dörken,et al. Brain metastases in breast cancer: prognostic factors and management. , 1999, European journal of cancer.
[6] K. Kelly,et al. Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? , 1998, Lung cancer.
[7] A. Gregor,et al. The treatment of brain metastases from lung cancer. , 1998, Lung cancer.
[8] H. Minn,et al. Prognosis of patients treated for intracranial metastases with whole-brain irradiation. , 1998, Annals of medicine.
[9] E. Arbit,et al. Surgical treatment of 70 patients with brain metastases from breast carcinoma , 1997, Cancer.
[10] W. Hall,et al. Brain metastases: Histology, multiplicity, surgery, and survival , 1996 .
[11] B. Young,et al. Demographics of brain metastasis. , 1996, Neurosurgery clinics of North America.